융복합 의료제품 시장

Drug-device Combination Products Market - Scope of Report

TMR's report on the global Drug-device Combination Products Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Drug-device Combination Products Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Drug-device Combination Products Market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Drug-device Combination Products Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Drug-device Combination Products Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Drug-device Combination Products Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Drug-device Combination Products Market .

The report delves into the competitive landscape of the global Drug-device Combination Products Market . Key players operating in the global Drug-device Combination Products Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Drug-device Combination Products Market profiled in this report.

Key Questions Answered in Global Drug-device Combination Products Market Report:

• What are the opportunities in the global Drug-device Combination Products Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Drug-device Combination Products Market - Research Objectives and Research Approach

The comprehensive report on the global Drug-device Combination Products Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Drug-device Combination Products Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Drug-device Combination Products Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Drug-device Combination Products Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Drug-device Combination Products Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Regulatory Landscape across Key Regions / Countries
• 5.2. Market Trends
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTEL Analysis
• 5.5. Key Purchase Metrics for End-users
• 5.6. Brand and Pricing Analysis
• 5.7. Value Chain Analysis
• 5.8. Technological Advancement

6. Global Drug-device Combination Products Market Analysis and Forecasts, By Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Product Type, 2020 to 2035
  • 6.3.1. Injectable Drug Delivery Devices
    • 6.3.1.1. Pen Injectors
    • 6.3.1.2. Autoinjectors
    • 6.3.1.3. Pre-Filled Syringes
    • 6.3.1.4. Others
  • 6.3.2. Infusion Pumps
    • 6.3.2.1. Volumetric
    • 6.3.2.2. Syringes
    • 6.3.2.3. Ambulatory
    • 6.3.2.4. Implantable
    • 6.3.2.5. Insulin
    • 6.3.2.6. Others
  • 6.3.3. Orthopedic Combination Products
    • 6.3.3.1. Bone Graft Implants
    • 6.3.3.2. Antibiotic Bone Cement
  • 6.3.4. Transdermal Patches
  • 6.3.5. Drug Eluting Stents
    • 6.3.5.1. Peripheral Vascular Stents
    • 6.3.5.2. Drug Eluting Stents
  • 6.3.6. Inhalers
    • 6.3.6.1. Dry Powder
    • 6.3.6.2. Nebulizers
    • 6.3.6.3. Metered Dose
  • 6.3.7. Others
• 6.4. Market Attractiveness By Product Type

7. Global Drug-device Combination Products Market Analysis and Forecasts, By Application

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Application, 2020 to 2035
  • 7.3.1. Diabetes Management
  • 7.3.2. Respiratory Diseases
  • 7.3.3. Eye Diseases
  • 7.3.4. Autoimmune Diseases
  • 7.3.5. Cancer
  • 7.3.6. Pain Management
  • 7.3.7. Infectious Diseases
  • 7.3.8. Cardiovascular Diseases
  • 7.3.9. Obesity Management
  • 7.3.10. Others
• 7.4. Market Attractiveness By Application

8. Global Drug-device Combination Products Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020 to 2035
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Ambulatory Surgical Centers
  • 8.3.4. Home Care Centers
  • 8.3.5. Others
• 8.4. Market Attractiveness By End-user

9. Global Drug-device Combination Products Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Drug-device Combination Products Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Product Type, 2020 to 2035
  • 10.2.1. Injectable Drug Delivery Devices
    • 10.2.1.1. Pen Injectors
    • 10.2.1.2. Autoinjectors
    • 10.2.1.3. Pre-Filled Syringes
    • 10.2.1.4. Others
  • 10.2.2. Infusion Pumps
    • 10.2.2.1. Volumetric
    • 10.2.2.2. Syringes
    • 10.2.2.3. Ambulatory
    • 10.2.2.4. Implantable
    • 10.2.2.5. Insulin
    • 10.2.2.6. Others
  • 10.2.3. Orthopedic Combination Products
    • 10.2.3.1. Bone Graft Implants
    • 10.2.3.2. Antibiotic Bone Cement
  • 10.2.4. Transdermal Patches
  • 10.2.5. Drug Eluting Stents
    • 10.2.5.1. Peripheral Vascular Stents
    • 10.2.5.2. Drug Eluting Stents
  • 10.2.6. Inhalers
    • 10.2.6.1. Dry Powder
    • 10.2.6.2. Nebulizers
    • 10.2.6.3. Metered Dose
  • 10.2.7. Others
• 10.3. Market Value Forecast By Application, 2020 to 2035
  • 10.3.1. Diabetes Management
  • 10.3.2. Respiratory Diseases
  • 10.3.3. Eye Diseases
  • 10.3.4. Autoimmune Diseases
  • 10.3.5. Cancer
  • 10.3.6. Pain Management
  • 10.3.7. Infectious Diseases
  • 10.3.8. Cardiovascular Diseases
  • 10.3.9. Obesity Management
  • 10.3.10. Others
• 10.4. Market Value Forecast By End-user, 2020 to 2035
  • 10.4.1. Hospitals
  • 10.4.2. Clinics
  • 10.4.3. Ambulatory Surgical Centers
  • 10.4.4. Home Care Centers
  • 10.4.5. Others
• 10.5. Market Value Forecast By Country, 2020 to 2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Product Type
  • 10.6.2. By Application
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Drug-device Combination Products Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Product Type, 2020 to 2035
  • 11.2.1. Injectable Drug Delivery Devices
    • 11.2.1.1. Pen Injectors
    • 11.2.1.2. Autoinjectors
    • 11.2.1.3. Pre-Filled Syringes
    • 11.2.1.4. Others
  • 11.2.2. Infusion Pumps
    • 11.2.2.1. Volumetric
    • 11.2.2.2. Syringes
    • 11.2.2.3. Ambulatory
    • 11.2.2.4. Implantable
    • 11.2.2.5. Insulin
    • 11.2.2.6. Others
  • 11.2.3. Orthopedic Combination Products
    • 11.2.3.1. Bone Graft Implants
    • 11.2.3.2. Antibiotic Bone Cement
  • 11.2.4. Transdermal Patches
  • 11.2.5. Drug Eluting Stents
    • 11.2.5.1. Peripheral Vascular Stents
    • 11.2.5.2. Drug Eluting Stents
  • 11.2.6. Inhalers
    • 11.2.6.1. Dry Powder
    • 11.2.6.2. Nebulizers
    • 11.2.6.3. Metered Dose
  • 11.2.7. Others
• 11.3. Market Value Forecast By Application, 2020 to 2035
  • 11.3.1. Diabetes Management
  • 11.3.2. Respiratory Diseases
  • 11.3.3. Eye Diseases
  • 11.3.4. Autoimmune Diseases
  • 11.3.5. Cancer
  • 11.3.6. Pain Management
  • 11.3.7. Infectious Diseases
  • 11.3.8. Cardiovascular Diseases
  • 11.3.9. Obesity Management
  • 11.3.10. Others
• 11.4. Market Value Forecast By End-user, 2020 to 2035
  • 11.4.1. Hospitals
  • 11.4.2. Clinics
  • 11.4.3. Ambulatory Surgical Centers
  • 11.4.4. Home Care Centers
  • 11.4.5. Others
• 11.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Switzerland
  • 11.5.7. The Netherlands
  • 11.5.8. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Product Type
  • 11.6.2. By Application
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Drug-device Combination Products Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Product Type, 2020 to 2035
  • 12.2.1. Injectable Drug Delivery Devices
    • 12.2.1.1. Pen Injectors
    • 12.2.1.2. Autoinjectors
    • 12.2.1.3. Pre-Filled Syringes
    • 12.2.1.4. Others
  • 12.2.2. Infusion Pumps
    • 12.2.2.1. Volumetric
    • 12.2.2.2. Syringes
    • 12.2.2.3. Ambulatory
    • 12.2.2.4. Implantable
    • 12.2.2.5. Insulin
    • 12.2.2.6. Others
  • 12.2.3. Orthopedic Combination Products
    • 12.2.3.1. Bone Graft Implants
    • 12.2.3.2. Antibiotic Bone Cement
  • 12.2.4. Transdermal Patches
  • 12.2.5. Drug Eluting Stents
    • 12.2.5.1. Peripheral Vascular Stents
    • 12.2.5.2. Drug Eluting Stents
  • 12.2.6. Inhalers
    • 12.2.6.1. Dry Powder
    • 12.2.6.2. Nebulizers
    • 12.2.6.3. Metered Dose
  • 12.2.7. Others
• 12.3. Market Value Forecast By Application, 2020 to 2035
  • 12.3.1. Diabetes Management
  • 12.3.2. Respiratory Diseases
  • 12.3.3. Eye Diseases
  • 12.3.4. Autoimmune Diseases
  • 12.3.5. Cancer
  • 12.3.6. Pain Management
  • 12.3.7. Infectious Diseases
  • 12.3.8. Cardiovascular Diseases
  • 12.3.9. Obesity Management
  • 12.3.10. Others
• 12.4. Market Value Forecast By End-user, 2020 to 2035
  • 12.4.1. Hospitals
  • 12.4.2. Clinics
  • 12.4.3. Ambulatory Surgical Centers
  • 12.4.4. Home Care Centers
  • 12.4.5. Others
• 12.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. South Korea
  • 12.5.6. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Product Type
  • 12.6.2. By Application
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Drug-device Combination Products Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Product Type, 2020 to 2035
  • 13.2.1. Injectable Drug Delivery Devices
    • 13.2.1.1. Pen Injectors
    • 13.2.1.2. Autoinjectors
    • 13.2.1.3. Pre-Filled Syringes
    • 13.2.1.4. Others
  • 13.2.2. Infusion Pumps
    • 13.2.2.1. Volumetric
    • 13.2.2.2. Syringes
    • 13.2.2.3. Ambulatory
    • 13.2.2.4. Implantable
    • 13.2.2.5. Insulin
    • 13.2.2.6. Others
  • 13.2.3. Orthopedic Combination Products
    • 13.2.3.1. Bone Graft Implants
    • 13.2.3.2. Antibiotic Bone Cement
  • 13.2.4. Transdermal Patches
  • 13.2.5. Drug Eluting Stents
    • 13.2.5.1. Peripheral Vascular Stents
    • 13.2.5.2. Drug Eluting Stents
  • 13.2.6. Inhalers
    • 13.2.6.1. Dry Powder
    • 13.2.6.2. Nebulizers
    • 13.2.6.3. Metered Dose
  • 13.2.7. Others
• 13.3. Market Value Forecast By Application, 2020 to 2035
  • 13.3.1. Diabetes Management
  • 13.3.2. Respiratory Diseases
  • 13.3.3. Eye Diseases
  • 13.3.4. Autoimmune Diseases
  • 13.3.5. Cancer
  • 13.3.6. Pain Management
  • 13.3.7. Infectious Diseases
  • 13.3.8. Cardiovascular Diseases
  • 13.3.9. Obesity Management
  • 13.3.10. Others
• 13.4. Market Value Forecast By End-user, 2020 to 2035
  • 13.4.1. Hospitals
  • 13.4.2. Clinics
  • 13.4.3. Ambulatory Surgical Centers
  • 13.4.4. Home Care Centers
  • 13.4.5. Others
• 13.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Product Type
  • 13.6.2. By Application
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Drug-device Combination Products Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Product Type, 2020 to 2035
  • 14.2.1. Injectable Drug Delivery Devices
    • 14.2.1.1. Pen Injectors
    • 14.2.1.2. Autoinjectors
    • 14.2.1.3. Pre-Filled Syringes
    • 14.2.1.4. Others
  • 14.2.2. Infusion Pumps
    • 14.2.2.1. Volumetric
    • 14.2.2.2. Syringes
    • 14.2.2.3. Ambulatory
    • 14.2.2.4. Implantable
    • 14.2.2.5. Insulin
    • 14.2.2.6. Others
  • 14.2.3. Orthopedic Combination Products
    • 14.2.3.1. Bone Graft Implants
    • 14.2.3.2. Antibiotic Bone Cement
  • 14.2.4. Transdermal Patches
  • 14.2.5. Drug Eluting Stents
    • 14.2.5.1. Peripheral Vascular Stents
    • 14.2.5.2. Drug Eluting Stents
  • 14.2.6. Inhalers
    • 14.2.6.1. Dry Powder
    • 14.2.6.2. Nebulizers
    • 14.2.6.3. Metered Dose
  • 14.2.7. Others
• 14.3. Market Value Forecast By Application, 2020 to 2035
  • 14.3.1. Diabetes Management
  • 14.3.2. Respiratory Diseases
  • 14.3.3. Eye Diseases
  • 14.3.4. Autoimmune Diseases
  • 14.3.5. Cancer
  • 14.3.6. Pain Management
  • 14.3.7. Infectious Diseases
  • 14.3.8. Cardiovascular Diseases
  • 14.3.9. Obesity Management
  • 14.3.10. Others
• 14.4. Market Value Forecast By End-user, 2020 to 2035
  • 14.4.1. Hospitals
  • 14.4.2. Clinics
  • 14.4.3. Ambulatory Surgical Centers
  • 14.4.4. Home Care Centers
  • 14.4.5. Others
• 14.5. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Product Type
  • 14.6.2. By Application
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. Abbott
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Eli Lilly and Company
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Medtronic
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Novo Nordisk A/S
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. Novartis AG
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Sanofi
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Boston Scientific Corporation or its affiliates.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. BD
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Merck KGaA
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. B. Braun SE
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. Stryker
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Gerresheimer AG
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Product Portfolio
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Narang Medical Limited.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Product Portfolio
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments
  • 15.3.14. Sparsha Pharma International Pvt Ltd
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Product Portfolio
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Developments
  • 15.3.15. Other Prominent Players
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Financial Overview
    • 15.3.15.3. Product Portfolio
    • 15.3.15.4. Business Strategies
    • 15.3.15.5. Recent Developments